02607.HK
Shanghai Pharmaceuticals Holding Co., Ltd
HKSE · Healthcare · Medical - Distribution · CN
HKD 11.57
+1.49%Year over year
Reported trailing growth
- Revenue
- +4.0%
- EBITDA
- -7.3%
- EBIT
- -20.6%
- EPS
- -22.1%
- Free cash flow
- +302.0%
- Operating cash flow
- +901.3%
Forward estimates
Based on analyst estimates
- Revenue
- -1.4%
- EBITDA
- +23.5%
- EPS
- -3.1%
Three-year CAGR
- Revenue
- +6.9%
- EBITDA
- +4.9%
- EBIT
- +3.3%
- Net income
- +0.6%
- EPS
- -1.5%
- Free cash flow
- +23.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026